About Immunicon
Immunicon is a Healthcare company based in Bryn Athyn (United States) founded in 1983 by Paul Liberti, and was acquired by CellSearch in June 2008. Cell and molecular-based diagnostics for cancer management are developed. Immunicon has raised $75.35 million across 5 funding rounds from investors including NIH, LHC Group and Canaan. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its competitors include NanoCellect Biomedical, Singulex and Cell Microsystems; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 1983 in Bryn Athyn, United States, Immunicon focused on biotechnology for cancer disease management. Platform technologies were developed to identify and characterize rare cells in blood, such as circulating tumor cells. Diagnostic and research products were commercialized, while analytical services were provided to pharmaceutical and biotechnology firms for therapeutic development. The company was acquired by Veridex in August 2008.
- Headquarters Bryn Athyn, United States
- Founders Paul Liberti
- Stage Acquired
- SectorsHealthcare
- Website immunicon.com
- Social LinkedIn
- Acquired by CellSearch (Jun 2008)
- Total Equity Funding$75.35M (USD)
in 5 rounds
- Latest Funding Round$940K (USD), Grant
Jun 2015
- InvestorsNIH
& 11 more
- Acquired byCellSearch
(Jun 2008)
Funding Insights of Immunicon
Immunicon has successfully raised a total of $75.35M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $940 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75.35M
- Total Rounds 5
- Last Round Grant — $940,000
- First Round $21.8M
(Sep 2000)
- Investors Count 11
All 5 funding rounds of Immunicon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $940,000 | Grant | – | – | |
| Apr 2008 | Grant | – | – | ||
| Jul 2003 | $24.75M | Series F | – | – | – |
| Jan 2002 | $28.8M | Series F | – | – | |
| Sep 2000 | $21.8M | Series D | – | – |
12 investors in total: 12 institutional.
Investors in Immunicon
Immunicon has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, LHC Group and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech-based companies are invested in by Wheatley Partners. | wheatleypartners.com | Great Neck, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Early-stage tech startups are funded by this venture capital firm. | flarecapital.com | Boston, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Early-stage companies are invested in globally by TL Ventures. | tl.ventures | Wayne, United States | ||
| mdscapital.com | ||||
Medrecruit is engaged in medical recruitment across Australasia. | medcapital.net | Robina, Australia | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
| ctmm.nl | ||||
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China |
Investor details for Immunicon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immunicon
1 people are tracked at Immunicon (1 in leadership).
| Name | Role | Group |
|---|---|---|
Paul Liberti | Founder | Leadership |
Complete people profiles for Immunicon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Immunicon
5 dated milestones of Immunicon across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Immunicon is founded.
- Funding First funding round of $21.8M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by CellSearch.
- Funding Latest funding round, Grant, of $940K.
Competitors of Immunicon
Immunicon has 3 listed competitors in our database, 3 of them funded. They include NanoCellect Biomedical, Singulex and Cell Microsystems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanocellect.com | 2009 | San Diego, United States | $78.15M | 84 | Develops flow cytometry and cell sorting technology | |
| singulex.com | 1997 | Alameda, United States | $140.94M | 236 | Single-molecule counting technology is developed for cardiovascular biomarker detection. | |
| cellmicrosystems.com | 2009 | Durham, United States | $19.1M | Developer of a technology to isolate and recover single cells for molecular analysis |
Detailed competitors of Immunicon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immunicon
Websites that share an audience with Immunicon (immunicon.com).
Websites whose visitors overlap most with Immunicon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| atdbio.com | 100% | 29.3K | #886,988 | View details | |
| eurochem.co.uk | 100% | View details | |||
capsulution.com | capsulution.com | 100% | #3,311,802 | – | |
| firstnano.com | 100% | View details | |||
| hybridplastics.com | 100% | 1.8K | #6,871,765 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Immunicon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Immunicon (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immunicon
Immunicon was founded in 1983 and raised its 1st funding round 17 years after it was founded.
Immunicon is headquartered in Bryn Athyn, United States. It is registered at Bryn Athyn, Pennsylvania, United States.
Immunicon is a funded company, having raised a total of $75.35M across 5 funding rounds to date. The company's 1st funding round was a Series D of $21.8M, raised on Sep 2000.
Founded in 1983 in Bryn Athyn, United States, Immunicon focused on biotechnology for cancer disease management. Platform technologies were developed to identify and characterize rare cells in blood, such as circulating tumor cells. Diagnostic and research products were commercialized, while analytical services were provided to pharmaceutical and biotechnology firms for therapeutic development. The company was acquired by Veridex in August 2008.
Immunicon's top competitors include NanoCellect Biomedical, Singulex and Cell Microsystems.
Immunicon has 12 investors. Key investors include NIH, LHC Group, Canaan, Burrill and Company, and CellSearch.
Yes. Immunicon was acquired by CellSearch in June 2008.